IE
ACHV icon

Israel Englander’s Achieve Life Sciences ACHV Stock Holding History

Israel Englander’s Portfolio ACHV Stock Details ACHV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-136
Closed -$1.12M – 3647
2014
Q2 		$1.12M Hold
136
– – ﹤0.01% 2139
2014
Q1 		$3.53M Buy
+136
New +$3.34M 0.01% 1408

Other funds holding ACHV

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Israel Englander's ACHV Position: Q2 2026 in Review

Israel Englander sold out of Achieve Life Sciences (ACHV) in Q2 2026, closing a stake of 1,077,338 shares — an estimated $3.17M sold.

Israel Englander first reported a position in ACHV in Q4 2013 and held it in 20 quarters. The position peaked at $6.75M in Q4 2025. 110 funds tracked by Wall St. Rank hold ACHV as of Q2 2026.

  • Israel Englander reported no remaining Achieve Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 1,077,338 Achieve Life Sciences shares in Q2 2026, an estimated $3.17M.
  • Israel Englander first reported a position in Achieve Life Sciences in Q4 2013 and held it in 20 quarters.
  • Israel Englander's Achieve Life Sciences position peaked at $6.75M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.